Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536393 | 0.89 | NR1H4 (0.50) | NR1H4KCNH2GAAMAPT | |
| SCHEMBL4525459 | 0.88 | NR1H4 (0.47) | NR1H4KCNH2HRH3 | |
| SCHEMBL1243051 | 0.86 | NR1H4 (0.63) | NR1H4KCNH2HRH3 | |
| SCHEMBL4525870 | 0.84 | NR1H4 (0.43) | NR1H4KCNH2MAPTALDH1A1 | |
| SCHEMBL4533951 | 0.83 | NR1H4 (0.42) | NR1H4HRH3 | |
| SCHEMBL4525523 | 0.83 | NR1H4 (0.64) | NR1H4KCNH2 | |
| SCHEMBL4527308 | 0.82 | NR1H4 (0.64) | NR1H4KCNH2 | |
| SCHEMBL1969196 | 0.82 | NR1H4 (0.79) | NR1H4KCNH2 | |
| SCHEMBL4525379 | 0.81 | NR1H4 (0.46) | NR1H4KCNH2ALDH1A1 | |
| SCHEMBL4523021 | 0.80 | PARP1 (0.44) | NR1H4KCNH2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | WYETH (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | NR1H4, NR1H2, NR1I3 | NR1H4 1/4885KCNH2 4119/4885GAA 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.